Supplementary Table S1 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer

Elena Shagisultanova; William J. Gradishar; Ursa Brown-Glaberman; Pavani Chalasani; Andrew Brenner; Alison Stopeck; Hannah Parris; Dexiang Gao; Tessa McSpadden; José Mayordomo; Jennifer R. Diamond; Peter Kabos; Virginia F. Borges

doi:10.1158/1078-0432.30833942

Abstract

<p>Representativeness of the study participants</p>

Related Publications

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

William J. Gradishar , Sergei Tjulandin , Neville Davidson +5 more

Purpose ABI-007, the first biologically interactive albumin-bound paclitaxel in a nanameter particle, free of solvents, was compared with polyethylated castor oil–based standard...

2005 Journal of Clinical Oncology 2071 citations

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Javier Cortés , David W. Cescon , Hope S. Rugo +97 more

Pembrolizumab monotherapy showed durable antitumour activity and manageable safety in patients with metastatic triple-negative breast cancer. We aimed to examine whether the add...

2020 The Lancet 1658 citations

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

Richard S. Finn , Baek‐Yeol Ryoo , Philippe Merle +17 more

PURPOSE Pembrolizumab demonstrated antitumor activity and safety in the phase II KEYNOTE-224 trial in previously treated patients with advanced hepatocellular carcinoma (HCC). K...

2019 Journal of Clinical Oncology 1737 citations

The rtPA (Alteplase) 0- to 6-Hour Acute Stroke Trial, Part A (A0276g)

Wayne M. Clark , Gregory W. Albers , Kenneth P. Madden +1 more

Background and Purpose —The Thrombolytic Therapy in Acute Ischemic Stroke Study, which started in August of 1991, was designed to assess the efficacy and safety of intravenous r...

2000 Stroke 415 citations

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

Melody Cobleigh , Charles L. Vogel , Debu Tripathy +8 more

PURPOSE: Overexpression of the HER2 protein occurs in 25% to 30% of human breast cancers and leads to a particularly aggressive form of the disease. Efficacy and safety of recom...

1999 Journal of Clinical Oncology 2778 citations

Publication Info

Year: 2025
Type: article
Citations: 0
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Supplementary Table S1 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

OpenAlex

Cite This

APA Style

                            
                                    Elena Shagisultanova, 
                                
                                    William J. Gradishar, 
                                
                                    Ursa Brown-Glaberman
                                
                                et al.
                            
                            (2025). 
                            Supplementary Table S1 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer. 
                            
                            .
                            https://doi.org/10.1158/1078-0432.30833942

Identifiers

DOI: 10.1158/1078-0432.30833942